Back On Track: Repros Therapeutics Products Continues Advancement

By Brian L. Wilson:Thursday, we saw shares of the developmental biopharmaceutical company Repros Therapeutics (NASDAQ: RPRX) close over 76% higher by the closing bell, reacting to a press release issued by the company after Wednesday's trading.

By Brian L. Wilson: Repros Therapeutics Inc. (NASDAQ:RPRX) caught the attention of biotech investors after its ~120% rally in May, which sent the stock from a market cap of approximately $63 million to its current $140 million. Biotech investors looking at this firm's history can quickly note that the IPO for RPRX was initiated all the way back in 1993.

By Timeless Wealth:Repros Therapeutics (RPRX) is one of those rare companies that have been in 'development' for 24 - going on 25 - years. In their tenure, they've consistently underperformed investor expectations and burned through roughly $200 Million.

By InsiderInsights:Below are lists of the top 10 mainly open-market insider purchases and sales filed at the Securities and Exchange Commission Monday, May 14, 2012 as ranked by dollar value.

The Burrill Report submits: by MARIE DAGHLIAN

By StockPandit:2012 is so far the best year for Biotechnology and Drugs industry. So many stocks surged in the last two months based on clinical trial results, U.S. Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, European commission approval, recommendation from independent committees, partnership with big pharmaceuticals, acquisitions and so on.

Jason Chew submits: Pharmasset (VRUS) is a biotech company focused on the development of HCV therapeutics. It has multiple drugs in development, all based on its core strength in RNA nucleoside analog chemistry. The current standard of care for HCV is a combination of pegylated alpha interferon (IFN-α) and ribavirin taken for up to 48 weeks depending on patient response.

Ted Stamas submits:Nothing gets an investor wide-eyed like the prospect of jump starting his portfolio with a hot biotechnology stock that's reaching a boiling point. This is especially true if the jury is still out in regards to launching a new pharmaceutical in Phase III trials. Unfortunately, most promising drugs don't reach the light of day. As stated in a recent TheStreet Ratings Report: